AP1893A - Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof - Google Patents

Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof

Info

Publication number: AP1893A
Authority: AP; ARIPO
Prior art keywords: adenosine; receptor; compounds; compounds specific; receptors
Prior art date: 2000-12-01

Application number

APAP/P/2003/002807A

Other languages

English (en)

Other versions

AP2003002807A0 (en

Inventor

Arlindo L Castelhano

Original Assignee

Osi Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-12-01

Filing date

2001-11-30

Publication date

2008-09-23

2000-12-01 Priority claimed from US09/728,616 external-priority patent/US7160890B2/en

2000-12-01 Priority claimed from US09/728,316 external-priority patent/US6680322B2/en

2000-12-01 Priority claimed from US09/728,607 external-priority patent/US6664252B2/en

2001-11-30 Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc

2003-06-30 Publication of AP2003002807A0 publication Critical patent/AP2003002807A0/xx

2008-09-23 Application granted granted Critical

2008-09-23 Publication of AP1893A publication Critical patent/AP1893A/en

Links

OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title abstract 4
150000001875 compounds Chemical class 0.000 title abstract 4
239000002126 C01EB10 - Adenosine Substances 0.000 title abstract 2
229960005305 adenosine Drugs 0.000 title abstract 2
101150046889 ADORA3 gene Proteins 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
108020003175 receptors Proteins 0.000 abstract 1
102000005962 receptors Human genes 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Diabetes (AREA)
Hospice & Palliative Care (AREA)
Immunology (AREA)
Hematology (AREA)
Endocrinology (AREA)
Toxicology (AREA)
Psychology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biochemistry (AREA)
Anesthesiology (AREA)
Otolaryngology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

APAP/P/2003/002807A 2000-12-01 2001-11-30 Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof AP1893A (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US09/728,616 US7160890B2 (en)	1999-12-02	2000-12-01	Compounds specific to adenosine A3 receptor and uses thereof
US09/728,316 US6680322B2 (en)	1999-12-02	2000-12-01	Compounds specific to adenosine A1 receptors and uses thereof
US09/728,607 US6664252B2 (en)	1999-12-02	2000-12-01	4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
PCT/US2001/045280 WO2002057267A1 (en)	2000-12-01	2001-11-30	Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof

Publications (2)

Publication Number	Publication Date
AP2003002807A0 AP2003002807A0 (en)	2003-06-30
AP1893A true AP1893A (en)	2008-09-23

Family

ID=27419112

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
APAP/P/2003/002807A AP1893A (en)	2000-12-01	2001-11-30	Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof

Country Status (20)

Country	Link
EP (1)	EP1347980A4 (cs)
JP (1)	JP4579497B2 (cs)
CN (1)	CN1263757C (cs)
AP (1)	AP1893A (cs)
AU (1)	AU2002248151B2 (cs)
BR (1)	BR0115847A (cs)
CA (1)	CA2430577A1 (cs)
CZ (1)	CZ20031831A3 (cs)
EA (1)	EA007254B1 (cs)
HU (1)	HUP0400692A3 (cs)
IL (1)	IL155962A0 (cs)
ME (1)	MEP35308A (cs)
MX (1)	MXPA03004717A (cs)
NO (1)	NO327207B1 (cs)
NZ (1)	NZ525885A (cs)
OA (1)	OA13295A (cs)
PL (1)	PL363245A1 (cs)
WO (1)	WO2002057267A1 (cs)
YU (1)	YU42703A (cs)
ZA (1)	ZA200303729B (cs)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5090531A (en) *	1990-01-10	1992-02-25	Lord Corporation	Electrophoretic fluid differential
HUP0103836A3 (en)	1998-06-02	2003-05-28	Osi Pharmaceuticals Inc Uniond	Pyrrolo[2,3d]pyrimidine compositions and their use
US6680324B2 (en)	2000-12-01	2004-01-20	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (de) *	2001-10-04	2003-04-10	Merck Patent Gmbh	Pyrimidinderivate
JP2005529062A (ja)	2001-11-30	2005-09-29	オーエスアイ・ファーマスーティカルズ・インコーポレーテッド	アデノシンａ１及びａ３受容体に特異的な化合物とその使用
ATE466581T1 (de) *	2001-12-07	2010-05-15	Vertex Pharma	Verbindungen auf pyrimidin-basis als gsk-3-hemmer
DE60236458D1 (de)	2001-12-20	2010-07-01	Osi Pharm Inc	Pyrrolopyrimidin a2b selektive antagonistische verbindungen, deren synthese und verwendung
KR20040068317A (ko)	2001-12-20	2004-07-30	오에스아이 파마슈티컬스, 인코포레이티드	피리미딘 ａ₂ｂ 선택성 길항 화합물, 그의 합성 방법 및용도
EP1556053A4 (en) *	2002-10-31	2006-04-19	Amgen Inc	ANTI-INFLAMMATORY AGENTS
HUP0203976A3 (en) *	2002-11-15	2004-08-30	Sanofi Aventis	Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
UY29177A1 (es)	2004-10-25	2006-05-31	Astex Therapeutics Ltd	Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
MY179032A (en)	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
DE602006013792D1 (de) *	2005-02-18	2010-06-02	Solvay Pharm Gmbh	Pharmazeutische zusammensetzungen mit nep-inhibitoren, inhibitoren des endogenes endothelin produzierenden systems und diuretika
WO2007125321A2 (en)	2006-04-25	2007-11-08	Astex Therapeutics Limited	Purine and deazapurine derivatives as pharmaceutical compounds
US20070260203A1 (en) *	2006-05-04	2007-11-08	Allergan, Inc.	Vasoactive agent intraocular implant
TW200808819A (en) *	2006-06-19	2008-02-16	Solvay Pharm Gmbh	Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
BRPI0818533B8 (pt)	2007-10-11	2021-05-25	Astrazeneca Ab	composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
AR070127A1 (es)	2008-01-11	2010-03-17	Novartis Ag	Pirrolo - pirimidinas y pirrolo -piridinas
KR20100116607A (ko)	2008-01-11	2010-11-01	낫코 파마 리미티드	항암제로서의 신규한 피라졸로[3,4-ｄ]피리미딘 유도체
ME03589B (me)	2011-04-01	2020-07-20	Astrazeneca Ab	Terapeutski tretman
MX367640B (es)	2011-11-30	2019-08-29	Astrazeneca Ab	Tratamiento combinado del cáncer.
AU2013204533B2 (en)	2012-04-17	2017-02-02	Astrazeneca Ab	Crystalline forms
BR112014030416A2 (pt) *	2012-06-07	2017-06-27	Hoffmann La Roche	composto, métodos para a inibição da tankyrase 1 e para o tratamento do câncer, utilização de um composto, composição e invenção.
CN105473581B (zh) *	2013-06-21	2019-04-23	齐尼思表观遗传学有限公司	作为溴结构域抑制剂的新取代的双环化合物
KR102307566B1 (ko)	2013-06-21	2021-10-05	제니쓰 에피제네틱스 리미티드	신규한 바이사이클릭 브로모도메인 억제제
CA2919948C (en)	2013-07-31	2020-07-21	Zenith Epigenetics Corp.	Novel quinazolinones as bromodomain inhibitors
US10179125B2 (en)	2014-12-01	2019-01-15	Zenith Epigenetics Ltd.	Substituted pyridines as bromodomain inhibitors
HK1245246A1 (zh)	2014-12-01	2018-08-24	恒翼生物医药科技(上海)有限公司	作为溴域抑制剂的取代吡啶酮
WO2016092375A1 (en)	2014-12-11	2016-06-16	Zenith Epigenetics Corp.	Substituted heterocycles as bromodomain inhibitors
CN107406438B (zh)	2014-12-17	2021-05-14	恒翼生物医药科技(上海)有限公司	溴结构域的抑制剂
ES2962330T3 (es)	2015-01-20	2024-03-18	Wuxi Fortune Pharmaceutical Co Ltd	Inhibidor de jak
EP3290418B1 (en)	2015-04-29	2019-05-15	Wuxi Fortune Pharmaceutical Co., Ltd	Janus kinase (jak) inhibitors
DK3305788T3 (da)	2015-05-29	2020-09-28	Wuxi Fortune Pharmaceutical Co Ltd	Janus-kinase-hæmmer
CN105771672B (zh) *	2016-04-18	2018-03-02	天津工业大学	一种抗污染抗菌芳香聚酰胺反渗透复合膜及制备方法
CN108570054B (zh) *	2017-03-07	2021-07-16	广州再极医药科技有限公司	氨基嘧啶并五元杂环化合物、其中间体、制备方法、药物组合物及应用
CN108017584B (zh) *	2017-06-20	2021-03-23	南开大学	A3腺苷受体的小分子拮抗剂
WO2019233994A1 (en) *	2018-06-04	2019-12-12	Exscientia Ltd	Pyrazolopyrimidine compounds as adenosine receptor antagonists
CN110128316B (zh) *	2019-05-22	2021-08-31	北京大学深圳研究生院	5位取代的β-脯氨酸及其衍生物的制备方法
CN110272373B (zh) *	2019-07-02	2022-07-29	天津国际生物医药联合研究院	一种具有选择性的腺苷a1受体拮抗剂及其应用
CN114085178A (zh) *	2021-12-29	2022-02-25	苏州楚凯药业有限公司	一种4-甲基-1-丙基-2-氨基-1h-吡咯-3-腈的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999062518A1 (en) *	1998-06-02	1999-12-09	Osi Pharmaceuticals, Inc.	PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE
WO2001039777A1 (en) *	1999-12-02	2001-06-07	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
WO2003048120A2 (en) *	2001-11-30	2003-06-12	Osi Pharmaceuticals, Inc.	2-aryl pyrrologpyrimidines for a1 and a3 receptors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR9307646A (pt) *	1992-12-17	1999-05-25	Pfizer	Pirrolopirimidinas como antagonistas de crf
US5780450A (en) *	1995-11-21	1998-07-14	Alcon Laboratories, Inc.	Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage

2001
- 2001-11-30 BR BR0115847-3A patent/BR0115847A/pt not_active Application Discontinuation
- 2001-11-30 CN CNB018224601A patent/CN1263757C/zh not_active Expired - Fee Related
- 2001-11-30 CA CA002430577A patent/CA2430577A1/en not_active Abandoned
- 2001-11-30 WO PCT/US2001/045280 patent/WO2002057267A1/en not_active Ceased
- 2001-11-30 ME MEP-353/08A patent/MEP35308A/xx unknown
- 2001-11-30 EP EP01997029A patent/EP1347980A4/en not_active Ceased
- 2001-11-30 AP APAP/P/2003/002807A patent/AP1893A/en active
- 2001-11-30 EA EA200300628A patent/EA007254B1/ru not_active IP Right Cessation
- 2001-11-30 AU AU2002248151A patent/AU2002248151B2/en not_active Ceased
- 2001-11-30 JP JP2002557944A patent/JP4579497B2/ja not_active Expired - Fee Related
- 2001-11-30 MX MXPA03004717A patent/MXPA03004717A/es active IP Right Grant
- 2001-11-30 PL PL01363245A patent/PL363245A1/xx not_active Application Discontinuation
- 2001-11-30 HU HU0400692A patent/HUP0400692A3/hu unknown
- 2001-11-30 OA OA1200300148A patent/OA13295A/en unknown
- 2001-11-30 CZ CZ20031831A patent/CZ20031831A3/cs unknown
- 2001-11-30 YU YU42703A patent/YU42703A/sh unknown
- 2001-11-30 NZ NZ525885A patent/NZ525885A/en active IP Right Revival
- 2001-11-30 IL IL15596201A patent/IL155962A0/xx unknown
2003
- 2003-05-14 ZA ZA200303729A patent/ZA200303729B/en unknown
- 2003-06-02 NO NO20032482A patent/NO327207B1/no not_active IP Right Cessation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999062518A1 (en) *	1998-06-02	1999-12-09	Osi Pharmaceuticals, Inc.	PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE
WO2001039777A1 (en) *	1999-12-02	2001-06-07	Osi Pharmaceuticals, Inc.	Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
WO2003048120A2 (en) *	2001-11-30	2003-06-12	Osi Pharmaceuticals, Inc.	2-aryl pyrrologpyrimidines for a1 and a3 receptors

Also Published As

Publication number	Publication date
BR0115847A (pt)	2004-02-25
OA13295A (en)	2007-04-13
MXPA03004717A (es)	2004-06-30
JP4579497B2 (ja)	2010-11-10
AP2003002807A0 (en)	2003-06-30
EP1347980A1 (en)	2003-10-01
MEP35308A (en)	2011-02-10
NO20032482L (no)	2003-07-28
JP2004517896A (ja)	2004-06-17
EA200300628A1 (ru)	2003-12-25
YU42703A (sh)	2006-03-03
NZ525885A (en)	2005-01-28
ZA200303729B (en)	2004-05-14
CZ20031831A3 (cs)	2004-05-12
EP1347980A4 (en)	2005-02-09
CA2430577A1 (en)	2002-07-25
AU2002248151B2 (en)	2008-02-21
HUP0400692A2 (hu)	2004-07-28
CN1489590A (zh)	2004-04-14
WO2002057267A1 (en)	2002-07-25
IL155962A0 (en)	2003-12-23
NO20032482D0 (no)	2003-06-02
NO327207B1 (no)	2009-05-11
PL363245A1 (en)	2004-11-15
EA007254B1 (ru)	2006-08-25
CN1263757C (zh)	2006-07-12
HUP0400692A3 (en)	2007-09-28

Publication	Publication Date	Title
YU42703A (sh)	2006-03-03	Jedinjenja specifična za dobijanje adenozinske a1,a2a i a3 receptore i njihove primene
WO2001039777A8 (en)	2001-11-08	Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
WO2003048120A3 (en)	2003-09-04	2-aryl pyrrologpyrimidines for a1 and a3 receptors
NZ522326A (en)	2006-03-31	Adenosine A2A receptor antagonists
AP2003002911A0 (en)	2003-12-31	An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.
PT1194049E (pt)	2005-09-30	Peca de vestuario com capacidade respiratoria, para ser vestida com o intuito de melhorar o conforto do corpo humana
BR0115067A (pt)	2004-04-06	Análogos de gnrh para tratamento de incontinência urinária
MXPA03009185A (es)	2004-02-17	Antagonistas de receptor a2a de adenosina combinados con compuestos de actividad neurotrofica en el tratamiento de la enfermedad de parkinson.
EE200000253A (et)	2001-06-15	Seentevastase toimeaine kasutamine ravimite valmistamiseks, mis on ette nähtud mitteinvasiivsetest seenorganismidest tingitud haiguste raviks või vältimiseks
BR0309544A (pt)	2005-02-01	Preparação farmacêutica contendo oxicodona e naloxona
HRP20130602T1 (en)	2013-07-31	2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
GEP20094798B (en)	2009-10-26	(s,s)-reboxetine for treating chronic pain
WO2005097140A3 (en)	2006-08-17	Selective antagonists of a2a adenosine receptors
NO996583D0 (no)	1999-12-30	Absorberende gjenstander til engangsbruk, med forbedret tilpasning til kroppsanatomien
EE05174B1 (et)	2009-06-15	Kemokiini mutandi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nhtud hulgiskleroosi ja teiste meliinikaotusega seotud haiguste raviks
ES2156215T3 (es)	2001-06-16	Utilizacion de un conjugado en el tratamiento y/o diagnostico de enfermedades inflamatorias.
IL156069A0 (en)	2003-12-23	Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma
EE200100689A (et)	2003-02-17	IL6RIL6 kimääri kasutamine ravimi valmistamiseks,mis on ette nähtud neuroloogiliste haiguste ravimiseks, ning farmatseutiline kompositsioon
WO2007045705A3 (es)	2007-06-14	Compuestos para el tratamiento de la fibrilación auricular
TWI256388B (en)	2006-06-11	Pharmaceutical combination
MY142646A (en)	2010-12-15	Chemokine receptor antagonists and methods of use therefor
GB0028245D0 (en)	2001-01-03	New therapeutic use
GB9930085D0 (en)	2000-02-09	Medicaments
WO1999038500A3 (en)	2000-04-13	The human calcium-sensing receptor in the detection and treatment of cancer
AU2003264195A8 (en)	2008-02-28	Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system